4//SEC Filing
Nabriva Therapeutics Plc 4
Accession 0001179110-17-010236
CIK 0001703287other
Filed
Jul 6, 8:00 PM ET
Accepted
Jul 7, 9:29 PM ET
Size
7.4 KB
Accession
0001179110-17-010236
Insider Transaction Report
Form 4
HBM BIOVENTURES CAYMAN LTD
10% Owner
Transactions
- Sale
Ordinary Shares
2017-07-05$10.52/sh−2,562$26,960→ 2,569,315 total - Sale
Ordinary Shares
2017-07-07$10.50/sh−133$1,397→ 2,569,182 total
Footnotes (2)
- [F1]On June 23, 2017, Nabriva Therapeutics plc ("Nabriva plc") became the successor of Nabriva Therapeutics AG ("Nabriva AG") pursuant to an exchange offer. Pursuant to the exchange offer, each outstanding common share of Nabriva AG was exchanged for ten ordinary shares of Nabriva plc and each outstanding American Depositary Share of Nabriva AG, which represented one-tenth of one common share of Nabriva AG, was exchanged for one ordinary share of Nabriva plc. On prior reports filed by the reporting person subsequent to the completion of the exchange offer, all references to American Depositary Shares of Nabriva AG should be understood to refer to ordinary shares of Nabriva plc..
- [F2]The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions ranging from $10.50 to $10.74 Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price.
Documents
Issuer
Nabriva Therapeutics Plc
CIK 0001703287
Entity typeother
IncorporatedIreland
Related Parties
1- filerCIK 0001703287
Filing Metadata
- Form type
- 4
- Filed
- Jul 6, 8:00 PM ET
- Accepted
- Jul 7, 9:29 PM ET
- Size
- 7.4 KB